Category Archives: Business and Investments

Latest From Business and Investments

BIO’s Dave Thomas Talks VC Funding with Daniel Levine

72263479

Last week, BIO Industry Analysis’s Dave Thomas spoke with Daniel Levine for his weekly podcast, The Bio Report. Dave discussed BIO‘s Venture Funding of Therapeutic Innovation Report, of which he is the lead author. The report analyzes data from four venture capital databases – Thomson Reuters, BioCentury, Elsevier, and Evaluate Pharm – to investigate investor trends, examine investment in specific therapeutic areas and indications, and identify disease areas that might be struggling for early-stage venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO’s Next Generation Partnering System to Open April 2015

partnering-HP-300x312

You’ve found your lead investor. Now it’s time to get to the next stage, and the best place to do so is the 2015 BIO International Convention. You have a meeting with Pfizer at 9:00 a.m. followed by a meeting with AstraZeneca/MedImmune at 9:30 a.m. Then a 30 minute break. Then you have four meetings back to back with Sofinnova, Takeda Ventures, Gates Foundation and Merck. After a quick lunch it’s back to partnering: make Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

The Perfect Close

72263479

With a fast and furious finish, yesterday, March 2nd, the Nasdaq Composite (IXIC) closed at 5,008.10, marking the third day in history with a close above 5,000. Since 95% of US publicly traded biotech companies are listed on the Nasdaq exchange, the team at BIO couldn’t help but join the excitement. Back in 2000, the Nasdaq index was flourishing with dot coms. At that point there was no Facebook or Netflix and Google wasn’t public. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Choose Wisely My Friend- Survey Says, Identifying the Right R&D Partner is the Most Challenging Aspect of Outsourcing Market

b9e35848296c8b6718258607ece28d99

A recent survey conducted by BIO confirms the increasing reliance on R&D outsourcing as biotech and pharmaceutical companies indicate speed, flexibility, and access to specialized resources drive pipeline strategies/decisions.  Despite these biopharma companies having veteran teams with outsourcing experience, our survey results help quantify inefficiencies facing nearly every relevant organization. The survey polled a group of small biotech companies about their experience with CROs and other contract service providers.  Over 80% of the companies surveyed were actively outsourcing portions of their pre-clinical or clinical pipelines.  Nearly two-thirds of the companies surveyed dedicated more than 20% of their entire budget to these services in 2014.  In addition, every company surveyed plans on maintaining Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Kyle Bass Files Second IPR Petition

Attribution: Vlad Lazarenko via Wikimedia Commons

Today hedge fund manager Kyle Bass has continued his reported “short activist strategy” campaign by filing a second Inter Partes Review (IPR) petition with the U.S. Patent and Trademark Office (USPTO). BIO expressed grave concerns with this exploitation of the patent challenge system following Mr. Bass’ initial filing earlier this month. Follow the below links to read more. BIO’s prior statement issued following Kyle Bass’ first IPR Petition When The Deck is Stacked Against Innovators, Everyone Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , ,